<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the fourth most frequently diagnosed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>The liver and lung are the most common sites of distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The approval of newer chemotherapeutic agents such as <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, irinotecan, bevacizumab, cetuximab and panitumumab has significantly improved survival, yet the majority of patients still succumb to the disease in less than 2 years </plain></SENT>
<SENT sid="3" pm="."><plain>Novel therapeutic agents that can provide significant clinical benefit for metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients are needed </plain></SENT>
<SENT sid="4" pm="."><plain>Oncolytic vesicular <z:hpo ids='HP_0010280'>stomatitis</z:hpo> virus (VSV) is a promising tool as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutic agent </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we examined the feasibility of repeated intravenous infusions of rVSV in multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e>, compared with repeated hepatic arterial administration in multifocal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in immune competent rats </plain></SENT>
<SENT sid="6" pm="."><plain>We established a multifocal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> model or the multiple <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> model using a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line, RCN-H4, implanted into syngeneic F344/DuCrj rats </plain></SENT>
<SENT sid="7" pm="."><plain>4.0x10(6) plaque-forming units (pfu) of recombinant VSV vectors expressing mutant (L289A) <z:e sem="disease" ids="C0027983" disease_type="Disease or Syndrome" abbrv="">Newcastle disease</z:e> virus fusion protein [rVSV-NDV/F(L289A)] were administered 3 times for 3 consecutive days locally via the hepatic artery for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> or systemically via the penial vein for <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> model, significantly enhanced survival was observed with rVSV-NDV/F(L289A)-treated rats (P=0.0196) </plain></SENT>
<SENT sid="9" pm="."><plain>Median survival was 110 and 25 days, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, 4 out of 7 of the rVSV-NDV/F(L289A)-treated rats demonstrated long-term survival exceeding 100 days </plain></SENT>
<SENT sid="11" pm="."><plain>The long-term surviving rats were sacrificed to evaluate for residual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">Liver tumors</z:e> were not detected </plain></SENT>
<SENT sid="13" pm="."><plain>In the lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> model, median survival was 10 [VSV-NDV/F(L289A)-treated rats] and 7 days (control) </plain></SENT>
<SENT sid="14" pm="."><plain>Although survival was significantly prolonged (P&lt;0.001), none of the rats achieved long-term survival </plain></SENT>
<SENT sid="15" pm="."><plain>VSV virotherapy has potential for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> liver and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e>, although systemic venous delivery is much less effective than locoregional delivery such as hepatic arterial infusion </plain></SENT>
</text></document>